

Prasugrel Information

Indications

Prasugrel is the P2Y₁₂ antiplatelet drug of choice (in combination with aspirin) for patients undergoing primary percutaneous coronary intervention (PPCI).

Prasugrel may also be considered in cases of 'clopidogrel failure' (i.e. stent thrombosis due to presumed hypo-responsiveness to clopidogrel), or as monotherapy in patients with a true allergy to aspirin.

Prasugrel should only be initiated by a Cardiologist.

Contraindications / precautions

- History of stroke or TIA
- ≥75 years of age
- Weight < 60kg

An alternative P2Y₁₂ antiplatelet drug such as clopidogrel or ticagrelor should be used in the above patients.

Where dual antiplatelet therapy is required in combination with anticoagulation (i.e. triple therapy), clopidogrel and aspirin should be used (with PPI cover).

Dose

Loading dose - 60mg

Maintenance dose - 10mg OD

Duration of therapy

In general, prasugrel should be continued for 12 months (or according to the interventionist's directions)

Author: Marcus Jones

Approved by: Drug & Therapeutics Committee February 2022

Review date: February 2025